A multidisciplinary panel released evidence‑based guidelines endorsing therapeutic drug monitoring (TDM) for biologic therapies in inflammatory bowel disease. The guideline synthesizes trial and real‑world data to provide actionable recommendations on when to measure drug levels and anti‑drug antibodies to optimize dosing and improve outcomes. The multidisciplinary effort pooled input from gastroenterologists, pharmacologists and laboratorians to standardize TDM practice across induction and maintenance phases. The guidance addresses assay selection, timing of sampling, and thresholds for dose adjustment. Wider adoption of TDM could tighten therapeutic windows for biologics, inform payer coverage decisions, and shift clinical workflows toward personalized dosing; labs and diagnostics vendors may see increased demand for validated assays and rapid turnaround.